Advertisement

Surgical Endoscopy

, Volume 34, Issue 2, pp 899–906 | Cite as

Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer

  • Tatsunori Minamide
  • Yusuke Yoda
  • Keisuke Hori
  • Kensuke Shinmura
  • Yasuhiro Oono
  • Hiroaki Ikematsu
  • Tomonori YanoEmail author
Article

Abstract

Background

Photodynamic therapy (PDT) is a salvage treatment for local failure following chemoradiotherapy (CRT) for esophageal cancer. This study aimed to evaluate the efficacy and safety of salvage PDT using the second-generation photosensitizer, talaporfin sodium (L-PDT), and compare L-PDT to PDT using porfimer sodium (P-PDT).

Methods

We retrospectively analyzed clinical outcomes of patients treated with L-PDT and P-PDT. Patients with histologically proven local failure limited to the shallow muscularis propria layer (T2) after CRT or radiotherapy (RT) for esophageal cancer were enrolled.

Results

A total of 121 patients were enrolled in this study. L-PDT and P-PDT groups consisted of 44 and 77 patients, respectively. The overall local complete response (L-CR) rate was 62.1% (95% confidence interval [CI], 52.6–70.9), and the L-PDT group showed a better L-CR rate than did the P-PDT group (69.0% [95% CI 52.9–82.4] vs. 58.1% [95% CI 46.1–69.5]). The common complications of skin phototoxicity, esophageal stricture, and esophageal fistula were all less frequent in the L-PDT group than in the P-PDT group. The only treatment-related death in this study was in the P-PDT group. With a median follow-up period of 15.8 months (interquartile range 7.1–37.4) in all 121 patients, overall survival rate at 1 year was significantly higher among patients who achieved L-CR (91.2% [95% CI 80.2–96.3]) than among those who could not achieve L-CR with PDT (50.8% [95% CI 33.6–65.6]).

Conclusions

L-PDT represented better short-term outcomes than P-PDT as a salvage treatment for local failure following CRT or RT for esophageal cancer.

Keywords

Photodynamic therapy Talaporfin sodium Porfimer sodium Chemoradiotherapy Esophageal cancer 

Notes

Acknowledgments

We are grateful to our medical and nursing colleagues for their help.

Author contributions

TM, TY—conception and design of the study. TM, YY, TY—Analysis and interpretation of data. TM—Drafting of the article. TY—Critical revision of the article for important intellectual content. YY, KH, KS, YO, HI, TY—Final approval of the article.

Compliance with ethical standards

Disclosures

Drs Tatsunori Minamide, Yusuke Yoda, Keisuke Hori, Kensuke Shinmura, Yasuhiro Oono, Hiroaki Ikematsu, and Tomonori Yano have no conflict of interest or financial ties to disclose.

References

  1. 1.
    Cooper J, Guo M, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Radiation Therapy Oncology Group for the chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623–1627CrossRefGoogle Scholar
  2. 2.
    Minsky B, Pajak T, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174CrossRefGoogle Scholar
  3. 3.
    Swisher SG, Wynn P, Putnum JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123:173–183CrossRefGoogle Scholar
  4. 4.
    Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Mori M, Doki Y (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 100:442–446CrossRefGoogle Scholar
  5. 5.
    Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H (2009) Salvage esophagectomy after highdose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 137:49–54CrossRefGoogle Scholar
  6. 6.
    Chao YK, Chan SC, Chang HK, Liu YH, Wu YC, Hsieh MJ, Tseng CK, Liu HP (2009) Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol 35:289–294CrossRefGoogle Scholar
  7. 7.
    Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T (2009) Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 92:266–269CrossRefGoogle Scholar
  8. 8.
    Hattori S, Muto M, Ohtsu A, Boku N, Manabe T, Doi T, Ishikura S, Yoshida S (2003) EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 58:65–70CrossRefGoogle Scholar
  9. 9.
    Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, Ishikura S, Ohtsu A, Yoshida S (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40:717–721CrossRefGoogle Scholar
  10. 10.
    Yano T, Muto M, Minashi K, Ohtsu A, Yoshida S (2005) Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 62:31–36CrossRefGoogle Scholar
  11. 11.
    Yano T, Muto M, Minashi K, Iwasaki J, Kojima T, Fuse N, Doi T, Kaneko K, Ohtsu A (2012) Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer 131:1228–1234CrossRefGoogle Scholar
  12. 12.
    Yano T, Muto M, Minashi K, Onozawa M, Nihei K, Ishikura S, Kaneko K, Ohtsu A (2011) Long-term results of salvage photodynamic therapy for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 43:657–663CrossRefGoogle Scholar
  13. 13.
    Dougherty TJ, Cooper MT, Mang TS (1990) Cutaneous phototoxic occurrence in patients receiving Photofrin. Lasers Surg Med 10:485–488CrossRefGoogle Scholar
  14. 14.
    Dougherty TJ, Marcus SL (1992) Photodynamic therapy. Eur J Cancer 28A:1734–1742CrossRefGoogle Scholar
  15. 15.
    Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M, Fukuoka M, Miyazawa T, Yana T, Matsui K, Shiraishi T, Horinouchi H (2003) Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 42:103–111CrossRefGoogle Scholar
  16. 16.
    Muragaki Y, Akimoto J, Maruyama T, Iseki H, Ikuta S, Nitta M, Maebayashi K, Saito T, Okada Y, Kaneko S, Matsumura A, Kuroiwa T, Karasawa K, Nakazato Y, Kayama T (2013) Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg 119:845–852CrossRefGoogle Scholar
  17. 17.
    Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, Tada H, Yamamoto Y, Kataoka H, Kakushima N, Ishihara R, Isomoto H, Muto M (2017) A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 8:22135–22144CrossRefGoogle Scholar
  18. 18.
    Hatogai K, Yano T, Kojima T, Onozawa M, Daiko H, Nomura S, Yoda Y, Doi T, Kaneko K, Ohtsu A (2016) Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc 83(1130–1139):e3Google Scholar
  19. 19.
    Leslie HS, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, HobokenGoogle Scholar
  20. 20.
    Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702CrossRefGoogle Scholar
  21. 21.
    Aizawa K, Okunaka T, Ohtani T, Kawabe H, Yasunaka Y, O’Hata S, Ohtomo N, Nishimiya K, Konaka C, Kato H, Hayata Y (1987) Localization of mono-l-aspartyl chlorin e6 (NPe6) in mouse tissues. Photochem Photobiol 46:789–794CrossRefGoogle Scholar
  22. 22.
    Nelson J, Roberts WG, Berns MW (1987) In vivo studies on the utilization of mono-l-aspartyl chlorin (NPe6) for the photodynamic therapy. Cancer Res 47:4681–4685PubMedGoogle Scholar
  23. 23.
    Overholt BF, Panjehpour M, Haydek JM (1999) Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc 49:1–7CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Tatsunori Minamide
    • 1
  • Yusuke Yoda
    • 1
  • Keisuke Hori
    • 1
  • Kensuke Shinmura
    • 1
  • Yasuhiro Oono
    • 1
  • Hiroaki Ikematsu
    • 1
  • Tomonori Yano
    • 1
    Email author
  1. 1.Department of Gastroenterology and EndoscopyNational Cancer Center Hospital EastKashiwaJapan

Personalised recommendations